BPC-157 vs TB-500 for dogs
The short answer
These are the two most frequently compared compounds in this field, and in the research literature they are more often studied together than against each other. The practical distinctions are dosing burden and cancer risk. BPC-157 is a daily injection with the better canine safety data and no cancer contraindication. TB-500 is dosed weekly, which many owners find far more sustainable, but it is contraindicated in any dog with known or suspected malignancy because it promotes angiogenesis and cell migration. For a young dog recovering from a defined soft tissue injury, the choice is largely about whether you can commit to daily injections. For an older dog whose cancer status is uncertain, BPC-157 is the more conservative option.
Side by side
| BPC-157 | TB-500 | |
|---|---|---|
| Evidence grade | Emerging evidence | Emerging evidence |
| Dosing frequency | Daily | Once or twice weekly |
| Canine-specific data | Published canine PK study in beagles | No canine PK; equine research since the early 2000s |
| Cancer contraindication | None established | Contraindicated with active or suspected cancer |
| Primary research focus | Tendon-to-bone healing, gut protection, angiogenesis | Cell migration, collagen deposition, wound repair |
| Competition status | Not specifically banned | Banned in competitive racing and detectable on testing |
| Full profile | BPC-157 for dogs | TB-500 for dogs |
Safety at a glance
BPC-157
BPC-157 has the most reassuring safety record of any compound on this site as it applies to dogs. A dedicated preclinical safety evaluation identified no lethal dose, no genotoxicity, and no teratogenicity, and the canine pharmacokinetic study reported good tolerance across seven days of repeated dosing at 30 mcg/kg — several times a typical clinical dose. The meaningful caveat is duration rather than dose: long-term continuous use in dogs has not been studied.
Is BPC-157 safe for dogs? →TB-500
TB-500 is generally well tolerated in the veterinary literature, with injection-site swelling the most common observation. The decisive safety question is not tolerance but cancer status: because the compound is associated with promoting new blood vessel growth and cell migration, it is contraindicated in dogs with active or suspected malignancy. Screening before starting is not optional. It is also banned in competitive racing and is detectable on testing.
Is TB-500 safe for dogs? →Common questions
Which is better for dogs, BPC-157 or TB-500?+
These are the two most frequently compared compounds in this field, and in the research literature they are more often studied together than against each other. The practical distinctions are dosing burden and cancer risk. BPC-157 is a daily injection with the better canine safety data and no cancer contraindication. TB-500 is dosed weekly, which many owners find far more sustainable, but it is contraindicated in any dog with known or suspected malignancy because it promotes angiogenesis and cell migration. For a young dog recovering from a defined soft tissue injury, the choice is largely about whether you can commit to daily injections. For an older dog whose cancer status is uncertain, BPC-157 is the more conservative option.
Can BPC-157 and TB-500 be used together in dogs?+
Combined protocols using both compounds appear in the literature, and they are more often studied together than as alternatives. Any combination increases the difficulty of attributing an adverse effect to a specific compound, so combining should be a deliberate decision made with your veterinarian rather than a default.
Which has better evidence in dogs, BPC-157 or TB-500?+
BPC-157 is graded emerging evidence with 6 cited studies; TB-500 is graded emerging evidence with 5 cited studies. Grades reflect the strength of published literature rather than an opinion about efficacy.
References
- 1.CANINE STUDYHe L, et al. Pharmacokinetics, distribution, metabolism and excretion of BPC 157 in rats and dogs. Frontiers in Pharmacology, 2022. PMID 36588722
- 2.CANINE STUDYXu C, et al. Preclinical safety evaluation of body protective compound-157. Regulatory Toxicology and Pharmacology, 2020. PMID 32334036
- 3.Vasireddi N, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine. Orthopaedic Journal of Sports Medicine, 2025. PMC12313605
- 4.Gwyer D, Wragg NM, Wilson SL Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019. PMID 30915550
- 5.Jozwiak M, et al. Multifunctionality of BPC 157: Literature and Patent Review. Pharmaceuticals, 2025. PMC11859134
- 6.CANINE STUDYJournal of the American Holistic Veterinary Medical Association Case report: canine stifle injury managed with BPC-157 and TB-500. JAHVM, 2023. View source
- 7.Kleinman HK, Sosne G Thymosin beta 4 promotes dermal healing: animal studies. Annals of the New York Academy of Sciences, 2010. PMID 20536453
- 8.Goldstein AL, Hannappel E, Sosne G, Kleinman HK Thymosin beta-4: a multi-functional regenerative peptide. Expert Opinion on Biological Therapy, 2012. PMID 22074294
- 9.Kwok WH, et al. Doping control analysis of TB-500 in equine urine and plasma. Journal of Chromatography B, 2013. PMID 23084823
- 10.Esposito S, et al. TB500/TB1000: understanding misbranded drugs. Drug Testing and Analysis, 2022. View source
Where to source research peptides
Compound quality is the variable most owners underestimate. Purity, accurate peptide content, and correct labelling determine whether any published dosing figure means anything at all. Pet & Peps Research publishes third-party testing on the compounds covered in this guide and supports this site.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.